FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 658 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR 11-Year-Old Cancer Survivor With One Leg Dances With Professional Tapper Lord... October 30, 2019 Ellen Gifts 25K To Army Veteran Who Fought Breast Cancer And... November 18, 2019 What Are Drug Shortages and How Can They Impact Care for... June 23, 2023 Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... July 16, 2021 Load more HOT NEWS Three cancer drugs approved for NHS use in Scotland EMA Recommends Granting a Conditional Marketing Authorisation for Sotorasib The Best And Worst Face Masks For COVID-19, Plus Face Masks... Opinion: ‘Why we need earlier diagnosis of cancer more than ever...
